Program
tapinarof
Also written as “Tapinarof cream, 1%”, “tapinarof cream, 1%” and “WBI-1001”.
Its studies are mostly in Psoriasis · Dermatitis, Atopic · Skin Diseases, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organon | 121 open or running | phase 4since Dec 26, 2022 | May 16, 2019 | Aug 2027phase 3 · NCT07265479 |
| GlaxoSmithKline | 80 open or running | phase 3since Jun 27, 2017 | Oct 31, 2013 | none ahead |
| Welichem Biotech | 30 open or running | phase 2since Feb 3, 2009 | Feb 3, 2009 | none ahead |
| Sun Pharmaceutical Industries | 10 open or running | phase 1since Apr 15, 2026 | Apr 15, 2026 | none ahead |
| Teva Pharmaceutical Industries | 10 open or running | phase 3since Dec 16, 2024 | Dec 16, 2024 | none ahead |
Also a collaborator on its studies: teva-pharmaceuticals-inc, iqvia-biotech, ppd-development-lp, q2-solutions and icardiac-technologies-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Feb 3, 2009.
- Jun 27, 2017Phase 1 study in PsoriasisGlaxoSmithKline · NCT03201978
- May 16, 2019Organon's first study: phase 3 study in PsoriasisNew to OrganonOrganon · NCT03956355 · 510 enrolled · United States, Canada
- Jun 10, 2019Phase 3 study in PsoriasisOrganon · NCT03983980 · 515 enrolled · United States, Canada
- Jul 23, 2019Phase 3 study in PsoriasisOrganon · NCT04053387 · 763 enrolled · United States, Canada
- Jul 24, 2019Phase 2 study in Plaque PsoriasisOrganon · NCT04042103 · 21 enrolled · United States
- Aug 16, 20212 phase 3 studies in Dermatitis, AtopicOrganon · NCT05014568, NCT05032859
- Oct 28, 20212 phase 3 studiesOrganon · NCT05172726, NCT05142774
- Nov 8, 2021Phase 2 study in Dermatitis, AtopicOrganon · NCT05186805 · 36 enrolled · United States, Canada
- Dec 26, 2022Phase 4 study in PsoriasisOrganon · NCT05680740 · 34 enrolled · United States
- Mar 14, 2023Phase 4 study in PsoriasisOrganon · NCT05789576 · 31 enrolled · United States
- Dec 16, 2024Teva Pharmaceutical Industries's first study: phase 3 study in Skin DiseasesNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT06742957 · 560 enrolled · United States
- Nov 21, 2025Phase 3 study in Dermatitis, AtopicOrganon · NCT07265479 · 187 enrolled · United States, Canada
- Apr 15, 2026Sun Pharmaceutical Industries's first study: phase 1 study in Plaque PsoriasisNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT07546214 · 575 enrolled · United States
- Oct 5, 2026Phase 3 study suspendedStudy stoppedNCT07265479
Ahead
- Aug 2027Primary completion: phase 3 study in Dermatitis, AtopicOrganon · NCT07265479
TargetBeta
“Aryl hydrocarbon receptor agonist”ChEMBL 37, by rule
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07546214Plaque Psoriasis · United States | 1 | Completed | Sun Pharmaceutical Industries | Mar 18, 2026 | 575 |
| NCT07265479Dermatitis, Atopic · United States, Canada | 3 | Active, not recruiting | Organon | Aug 2027 | 187 |
| NCT06742957Skin Diseases · United States | 3 | Completed | Teva Pharmaceutical Industries | Oct 7, 2025 | 560 |
| NCT05789576Psoriasis · United States | 4 | Completed | Organon | Jun 30, 2023 | 31 |
| NCT05680740Psoriasis · United States | 4 | Completed | Organon | May 18, 2023 | 34 |
| NCT05186805Dermatitis, Atopic · United States, Canada | 2 | Completed | Organon | Aug 24, 2022 | 36 |
| NCT05142774Dermatitis, Atopic · United States, Canada | 3 | Completed | Organon | Feb 29, 2024 | 728 |
| NCT05172726Plaque Psoriasis · United States, Canada | 3 | Completed | Organon | Oct 14, 2026 | 58 |
| NCT05032859Dermatitis, Atopic · United States, Canada | 3 | Completed | Organon | Feb 3, 2023 | 406 |
| NCT05014568Dermatitis, Atopic · United States, Canada | 3 | Completed | Organon | Mar 30, 2023 | 407 |
| NCT04042103Plaque Psoriasis · United States | 2 | Completed | Organon | Jan 9, 2020 | 21 |
| NCT04053387Psoriasis · United States, Canada | 3 | Completed | Organon | Apr 6, 2021 | 763 |
| NCT03983980Psoriasis · United States, Canada | 3 | Completed | Organon | May 13, 2020 | 515 |
| NCT03956355Psoriasis · United States, Canada | 3 | Completed | Organon | May 26, 2020 | 510 |
| NCT03202004Psoriasis | 3 | Withdrawn | GlaxoSmithKline | Sep 28, 2018 | 0 |
| NCT03201978Psoriasis | 1 | Withdrawn | GlaxoSmithKline | May 15, 2018 | 0 |
| NCT02564055Dermatitis, Atopic · United States, Canada, Japan | 2 | Completed | GlaxoSmithKline | Jan 1, 2017 | 247 |
| NCT02564042Psoriasis · United States, Canada, Japan | 2 | Completed | GlaxoSmithKline | Oct 1, 2016 | 227 |
| NCT02637206Dermatitis, Atopic · Japan | 1 | Completed | GlaxoSmithKline | Dec 2, 2015 | 26 |
| NCT02466152Dermatitis, Atopic · Canada | 1 | Completed | GlaxoSmithKline | Oct 27, 2015 | 11 |
| NCT02411162Dermatitis, Atopic · United States | 1 | Completed | GlaxoSmithKline | Sep 24, 2015 | 15 |
| NCT01984775Psoriasis · United States, Germany | 1 | Completed | GlaxoSmithKline | Jul 2, 2014 | 52 |
| NCT01098734Dermatitis, Atopic · Canada | 2 | Completed | Welichem Biotech | Oct 2010 | 148 |
| NCT01098721Psoriasis | 2 | Completed | Welichem Biotech | Sep 2010 | 61 |
| NCT00837551Dermatitis, Atopic · Canada | 2 | Completed | Welichem Biotech | Jun 2008 | 36 |
How it is read
Names in the registry
- “Tapinarof cream, 1%”, 4 entries
- “tapinarof cream, 1%”, 4 entries
- “WBI-1001”, 3 entries
- “Tapinarof”, 2 entries
- “GSK2894512 1% Cream”, 2 entries
Codes read as this program: GSK2894512.
Conditions, from the studies’ own filings
- Psoriasis, 13 studies
- Dermatitis, Atopic, 11 studies
- Skin Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.